HALIFAX, April 4, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that the Company's most advanced rapid HIV test, Reveal HIV, has been approved by the United States Agency for International Development (USAID) for inclusion on its list of approved rapid HIV tests.
Since its inception in 1986, the USAID HIV/AIDS program has invested over $7 billion to fight this global crisis. USAID is a key partner in the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the largest and most diverse HIV/AIDS prevention, care, and treatment initiative in the world.
With this approval and listing, MedMira's CE-marked rapid HIV tests, in addition to the previously listed FDA-approved rapid HIV test, are eligible for procurement with funds provided by USAID. This new approval further strengthens the Company's global rapid HIV test product line and serves as a strong foundation for MedMira to bring forward its other rapid diagnostic product lines, including Multiplo, for similar programs and approvals.
"We are very pleased with this latest approval and MedMira will continue to expand upon its portfolio of products within organizations such as USAID and PEPFAR in order to meet the increasing global demand, particularly in developing countries, for high quality rapid diagnostics," said Hermes Chan, CEO, MedMira Inc. "With the addition of three formats of MedMira's CE-marked rapid HIV test, projects funded by USAID and PEPFAR will be able to select the right format of the product for their testing initiative and further global HIV prevention and control efforts."
Organizations purchasing Reveal HIV from the approved USAID list can now select the format and packaging that best suits their program needs. The various Reveal HIV product configurations available through USAID offer customers choice, flexibility and convenience whether their testing program is taking place in a hospital setting, a voluntary testing clinic, or through a mobile testing vehicle.
Chan continued, "The Reveal HIV product line satisfies the needs of a broad range of USAID sponsored testing programs. Resource-constrained testing programs can use the convenient and cost-effective all-in-one package for fingerstick, point-of-care testing while reference laboratories and other clinical settngs can use the veni-puncture whole blood/serum/plasma formats for batch testing. The two laboratory formats offer customers significantly decreased administrative costs and testing time, a key advantage over other rapid HIV testing technology in large scale, government screening programs."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information:
Andrea Young, Corporate Communications
Email: [email protected]